TAGAMET
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is an injectable small-molecule histamine H2-receptor antagonist approved in 1977 by GSK. The specific indications are not provided in available data, but H2-blockers historically treat gastric acid-related conditions. This product represents a mature, established therapeutic agent with decades of clinical use.
LOE Approaching
As LOE approaches, the brand team is likely in triage or transition mode; expect smaller team size and strategic focus on niche positioning or combination therapies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAGAMET offers limited growth opportunity and suggests a career trajectory focused on operational excellence, regulatory stewardship, and cost management rather than innovation or commercial expansion. This role is best suited for professionals seeking stable, specialized expertise in mature product management or those transitioning to sunset-phase oversight.
Regulatory Affairs Specialist
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.